SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/D4FBFD594D702D24851BE57E05E50A5FB29FCB78C2676AFDBB28B96A17299B201562F38F48E2915386E52804C7889D95>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/D4FBFD594D702D24851BE57E05E50A5FB29FCB78C2676AFDBB28B96A17299B201562F38F48E2915386E52804C7889D95
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/D4FBFD594D702D24851BE57E05E50A5FB29FCB78C2676AFDBB28B96A17299B201562F38F48E2915386E52804C7889D95
http://www.w3.org/2000/01/rdf-schema#comment
"CLRN1 expression is potentially supported by a variety of retinal cells and the right combination of AAV vector dose promoter and delivery method needs to be selected to develop safe therapies for USH3 disorder."
xsd:string
http://purl.uniprot.org/uniprot/#_61EECC7759D91136F07B05DCB4F5288C6C029F82C1D7DD722763BCD734EA426A1195BCDEF294B1FC1BF190886E213696
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/D4FBFD594D702D24851BE57E05E50A5FB29FCB78C2676AFDBB28B96A17299B201562F38F48E2915386E52804C7889D95
http://purl.uniprot.org/uniprot/B7ZNE8
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/D4FBFD594D702D24851BE57E05E50A5FB29FCB78C2676AFDBB28B96A17299B201562F38F48E2915386E52804C7889D95
http://purl.uniprot.org/uniprot/#_B7ZNE8-mappedCitation-26881841
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/D4FBFD594D702D24851BE57E05E50A5FB29FCB78C2676AFDBB28B96A17299B201562F38F48E2915386E52804C7889D95